Evidence map›Paper›PMID 39744437›Full record

ArticleInternational journal of biological sciences2025

Quantitative Histopathology Analysis Based on Label-free Multiphoton Imaging for Breast Cancer Diagnosis and Neoadjuvant Immunotherapy Response Assessment.

Ruiqi Zhong, Ying Zhang, Wenzhuo Qiu, Kaipeng Zhang, Qianqian Feng, Xiuxue Cao, Qixin Huang, Yijing Zhang, Yuanyuan Guo, Jia Guo and 7 more

Abstract read
In one paragraph

Article in International journal of biological sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ruiqi Zhong4+4 Medical Doctor Program, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Ying ZhangAcademy of Advanced Interdisciplinary Study, Peking University, Beijing 100871, China.
Wenzhuo QiuAcademy of Advanced Interdisciplinary Study, Peking University, Beijing 100871, China.
Kaipeng Zhang4+4 Medical Doctor Program, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Qianqian FengDepartment of Pathology, China-Japan Friendship Hospital, Beijing 100029, China.
Xiuxue CaoDepartment of Pathology, China-Japan Friendship Hospital, Beijing 100029, China.
Qixin HuangDepartment of Pathology, China-Japan Friendship Hospital, Beijing 100029, China.
Yijing ZhangCollege of Future Technology, Peking University, Beijing 100871, China.
Yuanyuan GuoDepartment of Pathology, China-Japan Friendship Hospital, Beijing 100029, China.
Jia GuoDepartment of Pathology, China-Japan Friendship Hospital, Beijing 100029, China.
Lingyu ZhaoDepartment of Pathology, China-Japan Friendship Hospital, Beijing 100029, China.
Xiuhong WangDepartment of Pathology, China-Japan Friendship Hospital, Beijing 100029, China.
Shuhao WangThorough Lab, Thorough Future, Beijing 100036, China.
Lifang CuiDepartment of Pathology, China-Japan Friendship Hospital, Beijing 100029, China.
Aimin WangSchool of Electronics, Peking University, Beijing 100871, China.
Haili QianState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Fei MaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate diagnosis and assessment of breast cancer treatment responses are critical challenges in clinical practice, influencing patient treatment strategies and ultimately long-term prognosis. Currently, diagnosing breast cancer and evaluating the efficacy of neoadjuvant immunotherapy (NAIT) primarily rely on pathological identification of tumor cell morphology, count, and arrangement. However, when tumors are small, the tumors and tumor beds are difficult to detect; relying solely on tumor cell identification may lead to false negatives. In this study, we used the label-free multiphoton microscopy (MPM) method to quantitatively analyze breast tissue at the cellular, extracellular, and textural levels, and identified 11 key factors that can effectively distinguish different types of breast diseases. Key factors and clinical data are used to train a two-stage machine learning automatic diagnosis model, MINT, to accurately diagnose breast cancer. The classification capability of MINT was validated in independent cohorts (stage 1 AUC = 0.92; stage 2 AUC = 1.00). Furthermore, we also found that some factors could predict and assess the efficacy of NAIT, demonstrating the potential of label-free MPM in breast cancer diagnosis and treatment. We envision that in the future, label-free MPM can be used to complement stromal and textural information in pathological tissue, benefiting breast cancer diagnosis and neoadjuvant therapy efficacy prediction, thereby assisting clinicians in formulating personalized treatment plans.

Indexed as

Breast NeoplasmsImmunotherapyNeoadjuvant TherapyAdultFemaleHumansMachine LearningMicroscopy, Fluorescence, MultiphotonMiddle Agedbreast cancerextracellular matrixlabel-free multiphoton imagingneoadjuvant immunotherapyquantitative analysistexture

Identifiers

PMID39744437
PMCPMC11667811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.